Men with at least 3 GSTM1 genes were at a higher, but not significantly higher, risk of prostate cancer (OR: 2.55, 95% CI: 0.78–8.39); the trend for GSTM1 gene dose association was inconclusive (Ptrend 0.17). This evidence concerns the gene GSTM1 and prostate carcinoma.